natureresearch

Corresponding author(s): Kate E Broderick

Last updated by author(s): 2020/04/01

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see<u>Authors & Referees</u> and the<u>Editorial Policy Checklist</u>.

Statistics

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a	Confirmed			
	×	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement		
	×	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly		
	×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.		
X		A description of all covariates tested		
X		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons		
	×	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
×		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable</i> .		
×		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings		
×		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes		
×		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated		
		Our web collection on statistics for biologists contains articles on many of the points above.		

Software and code

Policy information about availability of computer code		
Data collection	FACS, ROSETTA	
Data analysis	FlowJo, Prism	
For manuaciate utilizing outcome leavithms or control to the recorded by the two described is published literature activates much be made qualible to adjace (review)		

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Provide your data availability statement here.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

× Life sciences

Behavioural & social sciences

Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

Sample size	Sample size was selected based upon mean and standard deviations observed in our previous vaccine studies in these animal models, and ability to detect statistical differences between experimental groups of this size.
Data exclusions	No data was excluded
Replication	The number of replicates is described and/or shown for each dataset, and supports the reproducibility of the findings.
Randomization	Age and sex matched animals were randomly allocated into each experimental group.
Blinding	Investigators were not blinded.

All studies must disclose on these points even when the disclosure is negative.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems Ν

nethous	/lethods	
---------	----------	--

n/a	Involved in the study	n/a	Involved in the study
	X Antibodies		ChIP-seq
	X Eukaryotic cell lines		x Flow cytometry
	Palaeontology		MRI-based neuroimaging
	X Animals and other organisms		
	Human research participants		
	Clinical data		

Antibodies

Antibodies used	PerCPCy5.5 Anti-mouse CD4 Clone RM4-5 (BD Bio #550954), APC Anti-mouse CD8 Clone 53-6.7 (BD Bio 553035), V450 Anti- mouse CD45 Clone 30-F11 (BD Bio 560501), APC-Cy7 Anti-mouse CD3 clone 145-2C11 (BD Bio 557596), BV605 Anti-mouse IFNg Clone XMG1.2 (Biolegend 505839), AlexaFluor700 Anti-mouse IL2 Clone JEs6-5H4 (BD Bio 561287), FITC Anti-mouse CD107a Clone 1D4B (BD Bio 553793), PE Anti-mouse TNFa Clone MP6-XT22 (BD Bio 554419), SARS Coronavirus Spike Protein Polyclonal Antibody (ThermoFisher PA1-41165), Rabbit IgG-heavy and light chain (Bethyl Laboratory A120-100P), beta-actin HRP (Santa Cruz Biotech sc-477778HRP) Anti-guinea pig IgG HRP (Sigma-Aldrich, A7289), anti-mouse IgG HRP (Sigma-Aldrich, A4416), Goat anti-human IgG-Fc fragment HRP (Bethyl Laboratory, A80-304P)
Validation	Validation based on each manufacturer's website.

Eukaryotic cell lines

olicy information about <u>cell lines</u>			
Cell line source(s)	293T (ATCC [®] CRL-3216 [™]), Expi293F (ThermoFisher)		
Authentication	The 293T cell line was purchased from American Type Cell Culture (www.atcc.org). Expi293 was purchased from ThermoFisher.		
Mycoplasma contamination	The cell lines were tested for mycoplasma contamination by American Type Cell Culture but once received in-house they were not tested.		
Commonly misidentified lines (See ICLAC register)	Name any commonly misidentified cell lines used in the study and provide a rationale for their use.		

Palaeontology

Specimen provenance	Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the
	issuing authority, the date of issue, and any identifying information).

ature research | reporting summary

Dating methods

Indicate where the specimens have been deposited to permit free access by other researchers.

If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.

Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research			
Laboratory animals	8 week old female BALB/C mice purchased from Jackson Labs housed at Acculab; 7 week old female Hartley guinea pigs purchased from Elm Hill Labs housed at Acculab; 8 week old female C57/BL6 mice purchased from Jackson Labs housed at Acculab; 6 week old female BALB/c mice were purchased from Charles River Laboratories and housed in the Wistar animal facility.		
Wild animals	the study did not involve wild animals		
Field-collected samples	the study did not involve field-collected samples		
Ethics oversight	all animal protocols were approved by the Wistar Institute or Acculab Institutional Animal Care and Use Committees (IACUC)		

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants

Policy information about studies involving human research participants

Population characteristics	Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."
Recruitment	Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.
Ethics oversight	Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about <u>clinical studies</u>

All manuscripts should comply with the ICMJEguidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration	Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.
Study protocol	Note where the full trial protocol can be accessed OR if not available, explain why.
Data collection	Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.
Outcomes	Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

ChIP-seq

Data deposition

Confirm that both raw and final processed data have been deposited in a public database such as <u>GEO</u>.

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links May remain private before publication.	For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.
Files in database submission	Provide a list of all files available in the database submission.
Genome browser session (e.g. <u>UCSC</u>)	Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.

Methodology

Replicates	Describe the experimental replicates, specifying number, type and replicate agreement.
Sequencing depth	Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.
Antibodies	Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.
Peak calling parameters	Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.
Data quality	Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.
Software	Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

Flow Cytometry

Plots

Confirm that:

X The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

🗴 The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

X All plots are contour plots with outliers or pseudocolor plots.

X A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	Mouse splenocytes were isolated and stimulated with peptides as described in the methodology.	
Instrument	BD FACS Canto	
Software	FlowJo version 10	
Cell population abundance	Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.	
Gating strategy	The gating strategy used was as to first gate on singlets, then lymphocytes followed by live CD45+ cells. Next CD3+ cells were gated and from that population CD4 and CD8 T-cells were gated. The different cytokines, IFNg, CD107a, IL2 were gated from each of the CD4 and CD8 T-cell populations.	
X Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.		

Magnetic resonance imaging

Experimental design Design type Indicate task or resting state; event-related or block design. Design specifications Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials. Behavioral performance measures State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).

Acquisition

Imaging type(s)	Specify: functional, structural, diffusion, perfusion.	
Field strength	Specify in Tesla	
Sequence & imaging parameters	Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.	
Area of acquisition	State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.	
Diffusion MRI Used	Not used	
Preprocessing		
Preprocessing software	Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).	
Normalization	If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.	
Normalization template	Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.	
Noise and artifact removal	Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).	
Volume censoring	Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.	
Statistical modeling & inference	e	
Model type and settings	Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).	
Effect(s) tested	Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.	
Specify type of analysis: 🗌 Whol	e brain 🗌 ROI-based 🔲 Both	
Statistic type for inference (See <u>Eklund et al. 2016</u>)	Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.	
Correction	Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).	
Models & analysis		

n/a Involved in the study Functional and/or effective connectivity Graph analysis Multivariate modeling or predictive analysis	
Functional and/or effective connectivity	Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).
Graph analysis	Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).
Multivariate modeling and predictive analysis	Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.